Clinical trial · Observational
Brazilian Reality of Hepatocellular Carcinoma
Brazilian Reality of Hepatocellular Carcinoma - BRA-HEP: Multicenter Retrospective Study (Real World Evidence - RWE)
NCT06230328CI-TRIAL-00095896BRA-HEPcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
National, multicenter, retrospective, non-randomized observational study (Real World Evidence-RWE) with the purpose of analyzing the epidemiological profile of Hepatocellular Carcinomas (BCLC A, B or C), clinical management, progression profile and overall survival of castrated patients treated in national oncology care reference centers, within the last 6 years (between 2017 to 2022).
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma by BCLC Stage | Hepatocellular Carcinoma by BCLC Stage | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma Stage I | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Hepatocellular Carcinoma Stage II | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Hepatocellular Carcinoma Stage III | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- Patients with early tumors at diagnosis (BCLC 0, A or B)
- label
- Cohort 2
- description
- Pacientes com tumores avançados ao diagnóstico (BCLC C ou D)
Primary outcomes (1)
- measure
- Epidemiological profile and pathological staging
- timeFrame
- At first diagnosis and over 6 years (Time of retrospective observational analysis of the study)
- description
- Identify the epidemiological profile and pathological staging of patients diagnosed with hepatocellular carcinoma treated at participating centers. Describe the treatments adopted and the response to the progression or non-progression of the disease.
Secondary outcomes (1)
- measure
- Description of clinical condition
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female; * Above 18 years old; * Hepatocellular carcinoma diagnosis (confirmed by biopsy or imaging); Exclusion Criteria: * Fibrollamelar carcinoma, hepatoblastoma, intrahepatic cholangiocarcinoma, neuroendocrine tumors or other less common types of liver tumors; * Patients with incomplete staging data; * Patients with only 1 visit to the participating site healthcare service, with loss to follow-up prior to the second visit to the participating site healthcare service; * Previous treatment for hepatocellular carcinoma in another institution; * Treatment with investigational drugs in a clinical trial.
References
Publications (1)
- DERIVEDDiniz Gomes Bugano D, Batista EC, Fernandes I, Sanches Faria Pinto G, Fiorin de Vasconcellos V, Cembranelli Teixeira R, Cunha Sousa Oliveira S, Kruschewsky Coutinho Araujo A, Lopes Ponte de Souza A, Cordeiro Felismino T, Fernando Weschenfelder R, Pedro Guedes Camandaroba M, Pereira M, Miranda Duarte F, Lopes da Silva M, Andrade de Souza V, Gabriely Costa Oliveira I, Dos Santos Sampaio B, Regina Lamas Assis S, Prado Dos Santos G, Monfardini F, Duarte Fagundes Moia D, Soares R, Vicente Rizzo L, Reis Alvares da Silva M. Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study. JCO Glob Oncol. 2026 Jun;12(6):e2500526. doi: 10.1200/GO-25-00526. Epub 2026 Jun 24. PMID 42341247